GABAA

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, March 18, 2024
Research, Epilepsy, PO, Seizure, Partnership, Risk, Patient, Tramadol, Acquisition, American Epilepsy Society, GABAA, Enrollment, NRF1, SBMA, Schedule, Hydromorphone, Society, Therapy, DSM-IV codes, Safety, GAERS, Morphine, Pain, FDA, AES, Annual general meeting, Food, Pharmaceutical industry

MIAMI, March 18, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the year ended December 31, 2023.

Key Points: 
  • “We made considerable progress across our pipeline of differentiated neurologic therapies in 2023," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • Pending additional financing, we look forward to progressing BAER-101 and IV tramadol for patients facing great unmet need.
  • R&D Expenses: Research and development expenses for the full year 2023 were $6.1 million, compared to $2.7 million in 2022.
  • G&A Expenses: General and administrative expenses for the full year 2023 were $4.2 million, compared to $5.3 million in 2022.

Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Retrieved on: 
Monday, March 18, 2024
Invention, Patent, IPR, Patient, Freedom, DSM-IV codes, GABAA, Pharmaceutical industry

STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator.

Key Points: 
  • STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator.
  • The inventions relate to the medical use of GT-002 in psychiatric disorders.
  • "When approved by USPTO these patent's will further strengthen our drug products and market position, giving Gabather a strong competitive advantage in providing the next generation neuropsychiatric drugs to the patients.
  • We will move forward into clinical trials in patients and identify the right partner for the continued development of GT-002" says Michael-Robin Witt, CEO of Gabather AB.

Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Retrieved on: 
Monday, March 18, 2024
Invention, Patent, IPR, Patient, Freedom, DSM-IV codes, GABAA, Pharmaceutical industry

STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator.

Key Points: 
  • STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator.
  • The inventions relate to the medical use of GT-002 in psychiatric disorders.
  • "When approved by USPTO these patent's will further strengthen our drug products and market position, giving Gabather a strong competitive advantage in providing the next generation neuropsychiatric drugs to the patients.
  • We will move forward into clinical trials in patients and identify the right partner for the continued development of GT-002" says Michael-Robin Witt, CEO of Gabather AB.

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Retrieved on: 
Thursday, February 22, 2024
Epilepsy, Pharmacology, DSM-IV codes, Research, GABAA, Drug resistance, 300X, Dizziness, Drug development, PAM, Volunteering, GAERS, Risk, Generalized tonic–clonic seizure, Deficit spending, Rat, Therapy, Ataxia, Memory, MED, Human, Cognition, Patient, Somnolence, Addiction, Partnership, Pharmaceutical industry

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.

Key Points: 
  • MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.
  • The publication describes the extent of anti-seizure activity of BAER-101 in the GAERS model, a widely used and translationally relevant animal model.
  • The study demonstrated full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg.
  • “The preclinical data published in Drug Development Research demonstrate BAER-101’s ability to fully suppress seizures in the GAERS model, a translational animal model for anti-seizure drug development with a documented high predictability of response in humans.

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on: 
Thursday, March 7, 2024
Anxiety, SAD, GABAA, Benzodiazepine, Ketamine, Deficit spending, Schizophrenia, BZD, Dog, Rat, PAM, Learning, Relaxation, Safety, Phencyclidine, Attention, Alpha, Memory, EEG, Patient, DSM-IV codes, Social, Lorazepam, Mouse, Brain, Medical imaging

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
  • The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
  • The secondary objective to demonstrate target engagement in human brain was also met.
  • The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on: 
Thursday, March 7, 2024
Anxiety, SAD, GABAA, Benzodiazepine, Ketamine, Deficit spending, Schizophrenia, BZD, Dog, Rat, PAM, Learning, Relaxation, Safety, Phencyclidine, Attention, Alpha, Memory, EEG, Patient, DSM-IV codes, Social, Lorazepam, Mouse, Brain, Medical imaging

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
  • The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
  • The secondary objective to demonstrate target engagement in human brain was also met.
  • The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Wednesday, February 14, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, PD, Research, Sale, Tremor, Health care, NMDA, Innovation, Webcast, Plasma, Incidence, GABAA, CIV, Standard of care, Deficit spending, Therapy, European Medicines Agency, Food and Drug Administration, MCI, NEST, HCP, Woman, Schedule, USAN, Postpartum depression, ODD, Safety, Prescription, Insurance, EMA, FDA, Food, Passport, DEA, PAM, DSM-IV codes, Risk, PPD, Patient, MHRA, Cognition, Essential tremor, Pharmaceutical industry

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $0.8 million in the fourth quarter of 2023, the first quarter of sales.
  • Net Loss: Net loss was $32.7 million for the fourth quarter of 2023 compared to $147.1 million for the same period in 2022.
  • ET to review its fourth quarter and full year 2023 financial results and discuss recent corporate updates.

RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

Retrieved on: 
Tuesday, February 13, 2024
Therapy, NINDS, RespireRx, GABAA, NIH, Neuropathic pain, Epilepsy, Addiction, Neuron, Narcotic, Female, Rat, OTC Markets Group, Drug discovery, Analgesic, Disability studies, Interim, University, PSPP, Pain management, Chronic pain, Research fellow, Patient, Heart, Initiative, Male, Hypoventilation, IND, DRS, Laboratory, Research, Pharmaceutical industry

Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.

Key Points: 
  • Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.
  • The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models.
  • These observations were made with both male and female rats in two measures each, in models of post-incision pain and spinal nerve ligation-induced persistent neuropathic pain.
  • These data trigger the advancement of KRM-II-81 within the NIH PSPP program where additional disease-specific pain models will be evaluated.

Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Research, Pharmaceutical, Consumer, Mental Health, Parenting, Clinical Trials, Science, Baby, Maternity, Neurology, Biotechnology, Women, FDA, Health, Conference, Essential tremor, PPD, PAM, Woman, Physician, DSM-IV codes, USAN, Therapy, HD, Postpartum depression, Standard of care, PD, GABAA, Webcast, Patient, NMDA, Pharmaceutical industry

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that Chief Executive Officer Barry Greene will discuss the Company’s key business drivers for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that Chief Executive Officer Barry Greene will discuss the Company’s key business drivers for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
  • Sage and Biogen field sales teams are engaging in promotional dialogues with health care professionals (HCPs) who actively identify and treat women with PPD.
  • Sage is advancing a portfolio of early-stage and clinical programs featuring internally discovered novel chemical entities targeting the GABAA and NMDA receptor systems.
  • A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient

Retrieved on: 
Thursday, January 4, 2024
Research fellow, Lead, IND, Epilepsy, Research, KRM, OTC Markets Group, Doctor of Philosophy, Drug tolerance, Seizure, Observation, GABAA, Bangladesh Technical Education Board, Neurosurgery, Patient, Craniotomy, Pharmaceutical industry

Cortical brain tissue surgically resected from the patient exhibited epileptiform bursting with microelectrode recordings.

Key Points: 
  • Cortical brain tissue surgically resected from the patient exhibited epileptiform bursting with microelectrode recordings.
  • When KRM–II–81, one of our lead GABAkines, was added the incubation fluid, the epileptiform activity in the excised brain tissue was fully suppressed.
  • Although our research team has observed suppression of activity previously in cortical tissue from epileptic patients, we have now observed recurrent epileptiform bursting in this patient’s tissue.
  • KRM-II-81 fully suppressed the epileptiform bursting, which returned when KRM-II-81 was removed from the incubation medium.